Join to View Full Profile
516 Pegram DrTupelo, MS 38801
Phone+1 662-844-6272
Fax+1 662-844-1603
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bradley Greenhaw, MD is a board certified dermatologist in Tupelo, Mississippi. He is currently licensed to practice medicine in Mississippi, Pennsylvania, and South Carolina.
Education & Training
Medical University of South CarolinaResidency, Dermatology, 2011 - 2014
University of Mississippi Medical CenterInternship, Internal Medicine, 2010 - 2011
University of Mississippi School of MedicineClass of 2010- University of Mississippi School of MedicineClass of 2010
Certifications & Licensure
MS State Medical License 2015 - 2025
PA State Medical License 2014 - 2016
SC State Medical License 2012 - 2015
American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- 7 citationsDevelopment and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous ...Ryan B. Thorpe, Kyle R. Covington, Hillary G. Caruso, Ann P. Quick, Olga Zolochevska
Journal of the American Academy of Dermatology. 2021-11-19 - 48 citationsMolecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patientsBradley N. Greenhaw, Kyle R. Covington, Sarah J. Kurley, Yıldıray Yeniay, Nhat Anh Cao
Journal of the American Academy of Dermatology. 2020-09-01 - 1 citationsReply to Problematic methodology in a systematic review and meta-analysis of DecisionDx-Melanoma.Bradley N. Greenhaw, Kyle R. Covington, Sarah J. Kurley, Yıldıray Yeniay, Nhat Anh Cao
Journal of the American Academy of Dermatology. 2020-06-08
Press Mentions
| Newsmakers |June 20th, 2021
Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic RiskApril 1st, 2020
31-GEP Test Predicts Likelihood of Metastasis for Cutaneous MelanomaMarch 5th, 2019- Join now to see all
